With the potential income and therapeutic benefit PYC-003 (targeting Polycystic Kidney Disease) could achieve, I would support PYC taking it through clinical trials on their own. I'd be happy with whatever it takes. Whether it be future crs or any of the other drugs in development licenced out, to finance the speedy progression to commercialization of PYC-003. Looking through past clinical trials, I believe PYC have the right approach and the best chance to date, of making a real-life changing impact for the suffers of ADPKD'1.
Ann: 2023 AGM Chairman's Address and CEO Presentation, page-36
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $606.5M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 12.5¢ | $17.86K | 137.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 1081168 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 505604 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |